Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

A Phase III, Open, Multicentre, Controlled Study to Evaluate the Long-Term Antibody Persistence at 2, 3, 4, 5, and 6 Years After a Booster Dose of Meningococcal Serogroup A, C, W-135, and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) or Meningitec® Administered in Healthy 5-Year-Old Children in Study MenACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (112036), Who Were Primed With the Same Vaccine in Study MenACWY-TT-039 (109670) at 12 Through 23 Months of Age

Category & Conditions:
Vaccine-related Conditions
Medicine:
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C0921001
Open Plain Language Summary Result:Click here